drugset / Trial / NCT01565902
Pharmacokinetics of BAF312 in Patients With Hepatic Impairment
Non-randomizedParallel-groupOpen-labelOther
Summary
This study will investigate the pharmacokinetics of BAF312 in patients with mild, moderate and severe hepatic impairment compared to healthy control subjects.
Timeline
- Start
- 2012-10
- Primary completion
- 2014-03
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAF312 | Unknown | 0.25 mg | Oral |
Indications
No indication recorded.